KRAS G12c Mutant
Cancers carrying the KRAS G12C mutation — the first KRAS variant with approved targeted drugs.
If KRAS G12c Mutant is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft. · Neoplasia · 2026-08-17
- A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. · Pharmacol Res · 2026-08-06
- KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. · Int J Mol Sci · 2026-07-20
- FDA Grants Breakthrough Therapy Designation to Olomorasib for KRAS G12C-Mutant Advanced Pancreatic Cancer - Oncodaily · FDA Oncology (Google News) · 2026-08-05 · usually covers Regulatory
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - PR Newswire · KRAS Mutation Research (Google News) · 2026-08-03 · usually covers Kras Research
What the reporting says
Across 18 tracked stories from 14 outlets, reporting on KRAS G12c Mutant most often describes regulatory approvals (4), acquisition (3).
It shows up alongside KRAS (18), Lung Cancer (8).
Two steps out: Colorectal Cancer (through KRAS, 18 shared stories on the weaker link); G12d (through KRAS, 18 shared stories on the weaker link); KRAS Mutant (through KRAS, 18 shared stories on the weaker link); Pancreatic Cancer (through KRAS, 18 shared stories on the weaker link).
Tracked since Mar 13, with coverage on 15 separate days — concentrated in Oncology and Pubmed Targeted.